Findings published in the journal New England Journal of Medicine provide further evidence that the Pfizer / BioNTech vaccine is effective against the delta variant among younger people, especially between the ages of 12 and 18 years. A study in Israel found that the estimated effectiveness of the vaccine against documented COVID-19 infection in adolescents was 90 percent and 93 percent against the symptomatic course of the disease on days 7 to 21 after the second dose.
Israeli health insurance company Clalit and researchers at Harvard University examined data from 94,354 vaccine recipients aged 12 to 18 years. The research took place from June to September, when the delta variant prevailed in Israel, the agency reported Reuters.
In its statement, the insurance company stated that its research is one of the largest expert evaluations of the effectiveness of the delta vaccine in the given age group. Earlier this week, an analysis published by the US Centers for Disease Control and Prevention (CDC) reported that Pfizer was 93 percent effective in preventing hospitalizations in people 12 to 18 years of age.